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ABSTRACT
Until recently, most reported cases of bacteraemia caused by multidrug-resistant strains of Enterobac-
teriacae producing an extended-spectrum b-lactamase (ESBL) in Europe have been nosocomial in origin.
However, increasing numbers of reports of community-acquired bacteraemia and urinary tract infection
caused by ESBL-producing microorganisms suggest that the geographical origin of patients should be
taken into account as a risk-factor for possible ESBL production. Early identiﬁcation of patients at high-
risk of infection with ESBL-producing microorganisms, based on their geographical origin and travel
history, should help to optimise initial antibiotic treatment strategies for severe urinary tract infections
in Europe.
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Key features distinguishing the antibiotic resist-
ance of Gram-negative bacteria from that of
Gram-positive bacteria include the rapid spread
of transmissible elements containing multiple
antibiotic resistance genes, and the higher relative
complexity of antibiotic resistance mechanisms.
Extended-spectrum b-lactamases (ESBLs) are
plasmid-encoded b-lactamases that confer signi-
ﬁcant resistance to all b-lactams except carba-
penems on their Gram-negative hosts. A series of
different enzymes with ESBL activity have been
identiﬁed in the past decade [1,2]. Microorgan-
isms producing ESBLs are multidrug-resistant
and constitute a signiﬁcant public health threat.
Until recently, ESBL-producing Enterobacteria-
ceae were considered to be exclusively nosoco-
mial pathogens [3]. However, recent studies
suggest that ESBLs are not restricted exclusively
to nosocomial bacteria, but can also be found in
strains causing urinary tract infection (UTI) and
bacteraemia in individuals with no previous
hospital contact [4]. Infection caused by ESBL-
producing organisms may become an emerging
problem in outpatient settings in various parts of
the world. Indeed, during the past 3 years there
have been reports from Spain, Israel, the UK,
Canada and Tanzania of signiﬁcant community-
acquired UTI, bacteraemia or colonisation with
ESBL-producing isolates of Escherichia coli [3].
Typically, patients initially develop UTI caused
by CTX-M-producing strains of E. coli. In partic-
ular, E. coli strains belonging to groups B2 and D
may exhibit a highly virulent phenotype,
although some studies have associated antibiotic
resistance with low-virulence phylogenetic
groups because multidrug-resistant E. coli strains
are commonly non-B2 group [6].
As an example of the difﬁculties that can be
encountered, a female, aged 42 years, from an
urban area in Lebanon was admitted to the
Hoˆpital Necker-Enfant Malades (Paris, France)
with acute fever. She had a recent medical history
of abdominal pain, diarrhoea and fever, suggest-
ing diverticulitis, and received an oral ﬂuoroqu-
inolone and metronidazole for 10 days. A
computerised tomography scan of the abdomen
revealed a heterogeneous hypodense lesion of
the right kidney, consistent with an extensive
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pyelonephritis. Urine and blood were collected
for microbiological cultures, and the patient
received intravenous cefotaxime and gentamicin.
Urine cultures yielded an E. coli isolate that was
susceptible only to imipenem and amikacin. Tests
with cefotaxime and clavulanate disks disclosed a
double-synergy indicating the production of an
ESBL. Therapy was switched to imipenem and
amikacin for 2 weeks. The patient was discharged
on day 21 and, 1 month later, was clinically and
microbiologically cured.
A retrospective analysis of ﬁles to assess the
impact of ESBLs at the same hospital revealed an
ESBL prevalence among clinical isolates of 4.7%
in 2004 and 5% in 2005, with E. coli representing
41% (2004) and 38% (2005) of these isolates.
Moreover, the percentage of ESBL-producing
microorganisms isolated within the ﬁrst 48 h of
hospitalisation, i.e., community-acquired, was
10% in 2004 and 6% in 2005, with E. coli repre-
senting 6% of these isolates. These ﬁndings
highlight the spread of ESBL-producing Entero-
bacteriaceae in the community in France, and also
the increased risk of inadequate antibiotic therapy
when patients are referred from geographical
areas with a high prevalence of ESBL-producing
organisms.
There is considerable geographical heterogen-
eity in the occurrence of ESBLs throughout the
world. The asynchrony in the emergence of these
enzymes among different countries may be a
consequence of differences in cephalosporin
usage, different methods of detecting ESBL-pro-
ducing bacteria, and disparities in terms of travel
to and from regions with a high prevalence of
ESBLs. As travel between Europe and neighbour-
ing countries with high ESBL prevalence rates in
Enterobacteriaceae is increasing, it can be anti-
cipated that further spread of ESBLs may occur in
the near future.
In support of this prediction, two recent reports
from Lebanon [6,7] noted a clear decrease in the
susceptibility of Enterobacteriaceae to all antibi-
otics in 1999–2001, and a continuous rising trend
over a 5-year period (1997–2001) in the percentage
of ESBL-producing isolates of Klebsiella pneumon-
iae. In the ﬁrst study, ESBL-producing Enterobac-
teriaceae were isolated from patients, healthcare
workers and healthy subjects, thereby indicating
the extent of the spread of these microorganisms
within the country. A study from Israel [8]
reported that 13.7% of 80 isolates of Enterobacte-
riaceae from blood samples obtained at hospital
admission produced an ESBL. A Spanish study
observed a signiﬁcant increase in the frequency of
ESBL stool carriers (from 2.1% to 7.5%) between
2001 and 2002 [9]. A further study from Israel [11]
of 311 non-hospitalised patients with community-
acquired UTI, including 128 patients infected with
EBSL-producing strains and 183 patients infected
with non-EBSL producers, revealed that hospital-
isation or antibiotic treatment in the preceding
3-month period, an age >60 years, diabetes, male
gender (OR 2.47, 95% CI 1.22–5.01), infection
with Klebsiella pneumoniae, and previous use of
third-generation cephalosporins, second-genera-
tion cephalosporins, a ﬂuoroquinolone or a peni-
cillin, were all independent risk-factors for
episodes of infection caused by ESBL-producing
bacteria.
The ﬁndings described above, in addition to the
reports in the literature, conﬁrm that ESBL-pro-
ducing Enterobacteriaceae are responsible for
community-acquired infections in Europe. Early
identiﬁcation of high-risk patients, based on their
geographical origin and travel history, should
help to optimise initial antimicrobial therapy for
severe UTIs in Europe. Production of ESBLs by
E. coli in the community setting is an emerging
problem that is still greatly underestimated.
Considering the implications for public health
that might result from the spread of organisms
producing ESBLs in the community, enhanced
surveillance efforts to monitor the spread of these
pathogens are clearly required.
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